| Glycyrrhetinic acid derivatives for treating hyperkalemia |
2023-5-15 |
2023-6-01 |
|
| Intestinal epithelial cell cultures |
2023-4-07 |
2023-10-05 |
|
| Hormone receptor modulators for treating metabolic mutagenic and fibrotic … |
2023-3-01 |
2023-5-12 |
|
| Compounds useful for treating gastrointestinal tract disorders |
2023-1-04 |
2023-4-11 |
|
| Composition and method for treating hyperkalemia |
2022-12-22 |
2023-3-01 |
|
| Substituted 4-Phenyl Pyridine Compounds As Non-Systemic TGR5 Agonists |
2022-12-01 |
2023-2-02 |
|
| Methods for inhibiting phosphate transport |
2022-11-14 |
2023-9-07 |
|
| Hormone receptor modulators for treating metabolic conditions and disorders |
2022-7-06 |
2023-5-04 |
|
| Compounds and methods for inhibiting nhe-mediated antiport in the treatment of … |
2022-4-01 |
2023-2-02 |
|
| Compounds and methods for inhibiting phosphate transport |
2022-3-11 |
2022-4-07 |
|
| Oral formulations of tenapanor |
2021-12-06 |
2023-10-11 |
|
| Oral formulations of tenapanor |
2021-12-06 |
2023-7-06 |
|
| Nhe3-binding compound and method for inhibiting phosphate transport |
2021-9-16 |
2021-12-23 |
|
| Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
2021-8-23 |
2022-10-26 |
|
| Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
2021-4-07 |
2023-8-08 |
2023-8-08 |
| Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists |
2021-2-25 |
2022-9-29 |
|
| Compounds and methods for inhibiting nhe-mediated antiport in treatment of … |
2019-8-22 |
2019-12-26 |
|
| Inhibitors of nhe-mediated antiport |
2019-7-08 |
2022-5-25 |
|
| Compounds and methods for inhibiting nhe-mediated antiport in the treatment of … |
2018-6-06 |
2020-7-30 |
|
| Compounds and methods for inhibiting nhe-mediated antiport in the treatment of … |
2018-5-29 |
2018-6-21 |
|
| Treatment of hepatic disorders |
2018-5-07 |
2018-11-08 |
|
| Compounds and methods for inhibiting nhe-mediated antiport in the treatment of … |
2018-1-09 |
2018-7-12 |
|
| Hormone receptor modulators for the treatment of metabolic conditions and … |
2017-8-23 |
2023-10-10 |
|
| Compositions and methods for treating hyperkalemia |
2017-3-29 |
2018-1-16 |
2018-1-16 |
| Compounds and methods for inhibiting nhe-mediated antiport in the treatment of … |
2017-1-09 |
2017-12-28 |
|
| SUBSTITUTED COMPOUNDS OF 4-PHENYL PIRIDINE AS NON-SYSTEMIC TGR5 AGONISTS |
2016-12-19 |
2018-3-28 |
|
| Compounds and methods for inhibiting phosphate transport |
2016-2-19 |
2017-2-09 |
|
| Non-systemic tgr5 agonists tgr5 |
2015-4-27 |
2015-10-30 |
|
| Compounds and methods for inhibiting phosphate transport |
2014-7-21 |
2016-3-08 |
2016-3-08 |
| Compounds and methods for inhibiting phosphate transport |
2014-7-21 |
2016-3-22 |
2016-3-22 |
| Compounds and methods for inhibiting phosphate transport |
2014-7-11 |
2015-6-11 |
|
| NHE3 BINDING COMPOUNDS AND METHODS TO INHIBIT PHOSPHATE TRANSPORTATION |
2014-4-11 |
2015-11-18 |
|
| Nhe3-binding compounds and methods for inhibiting phosphate transport |
2014-4-10 |
2021-5-27 |
|
| Compounds and methods for inhibiting phosphate transport |
2013-1-04 |
2014-1-23 |
|
| Formulations orales de ténapanor |
2021-12-06 |
2023-10-11 |
|
| Orale formulierungen von tenapanor |
2021-12-06 |
2023-10-11 |
|
| 用于治疗代谢病状和病症的激素受体调节剂 |
2017-8-23 |
2023-10-10 |
|